Epigenetics Industry Fueling by Rising Incidence of Chronic Illnesses

Published Date : 09 May 2023

The epigenetics industry revenue accounted for USD 1.9 billion in 2022 and is estimated to achieve a industry size of USD 6.35 billion by 2030, growing at a CAGR of 12.82% from 2023 to 2032. The industry is expected to expand because of the rising incidence of cancer and other chronic illnesses as well as the growing elderly population.

Market Growth:

Your surroundings and habits, including your diet and level of physical activity, are just as essential to your health as your genes. Epigenetics is the study of how changes in your surroundings and behavior can have an impact on how your DNA function. While epigenetic changes can alter how your body interprets a DNA code, they are reversible and do not alter your DNA sequenceing like hereditary changes do.

There may be a direct or tangential connection between epigenetic processes and several tumors, cardiovascular disorders, respiratory illnesses, reproductive problems, cognitive impairment, and challenges with autoimmune disorders. Pesticides, heavy metals, hormones, tobacco smoke, radiation, environmental factors, viruses, or inadequate nourishment are just a few of the factors that are becoming more prevalent, which is supporting industry expansion. 

Epigenetics Industry Report Scope:

Report Coverage Details
Revenue Share by 2023 USD 6.35 Billion
North America Share 40% in 2022
CAGR CAGR of 12.82%
Oncology Segment Share 70%
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Regional Snapshot:

Rapid advancements in healthcare infrastructure, the existence of significant regional players, significant expenditures in research and development, and the increasing incidence of cancer are a few of the factors contributing to the growth. Since many mammalian proteins, including growth hormones, insulin, antibodies, and vaccines, are manufactured industrially, the demand for protein expression systems is anticipated to rise along with rising expenditures by businesses in product research and development. Additionally, there is a rising need for the creation of cancer treatments in the United States, and significant investments are being made in the study of cancer genetics, which is anticipated to fuel the expansion of this industry in North America.

Asia Pacific is predicted to experience the industry's quickest growth during the anticipated time frame. The Asia Pacific industry is also anticipated to grow as a result of rising government financing for R&D projects, an increase in cancer incidence, and rising investments from industry participants in the area.

Impact of Covid-19:

Due to the significance of epigenetics in COVID-19 research, Covid has had a major effect on the growth of the epigenetics industry. For instance, epigenetic changes may be crucial in the onset of coronavirus illness complications, according to research that was published in Clinical Epigenetics in October 2020 under the title "The epigenetic implication in coronavirus infection and therapy." Even though there are many potential treatments, more study is desperately required to find a workable vaccine or more secure chemotherapy drugs, such as epigenetic therapies, to stop this viral epidemic and develop pre- and post-exposure COVID-19 prophylaxis. 

Market Dynamics:


Rising desire for the personalized medicines

The rising incidence of chronic illnesses like cancer, diabetes, and heart disease is one of the key factors fueling development in the epigenetics industry. There is increasing interest in creating epigenetic treatments that can target these changes because epigenetic modifications have been related to the onset and spread of these illnesses. The rising desire for personalized medication is another element fueling industry expansion. Epigenetic profiling can offer useful data about a person's propensity for contracting specific illnesses, and this data can be used to create individualized therapy regimens. 


Epigenomic data is only occasionally used in toxicity

Epigenomic information has only been partially applied in the field of toxicology, and our grasp of how epigenomic variability varies across various tissue types and groups has also been limited. To guarantee a thorough knowledge of epigenetic mechanisms that results in precise epigenomic variation mapping, novel methods must be developed. Lack of agreement on a typical epigenome for all tissue and cell types is a significant barrier to the implementation of epigenomic research in toxicology.


Technological advancement

Technology advancements that make epigenetic study and analysis more available and cheap are also helping the industry for epigenetics. For instance, recent advances in sequencing tools have made it possible for researchers to examine epigenetic changes at the genome-wide level, which was not feasible until recently. Creating epigenetic biomarkers that can be used to identify illnesses early, track the progression of diseases, and forecast therapy results is also becoming more and more popular. 

Overall, the epigenetics industry offers plenty of room for expansion for companies in the healthcare sector. There is an expanding need for goods and services that can address epigenetic modifications due to the rising prevalence of chronic illnesses, the rising desire for personalized treatment, and technological advancements. 

Product and Service Insights:

In terms of goods, reagents dominated the sector in 2022. DNA modifications and histones are epigenetic factors. Common epigenetics tools include antibodies, histones, PCR and electrophoresis kits, primers, buffers, and nucleic acid reagents. An advanced reagent called PyroMark Q24 employs novel pyrosequencing chemistry to offer sequence-based measurement and identification that was previously unattainable.  The kits industry is expected to experience the highest CAGR growth during the forecasted timeframe. Numerous biotechnology firms create ready-to-use tools for the detection of epigenetic changes. There are commercially accessible tools for DNA methylation research and histone alteration detection. 

Method Insights:

The industry is divided into DNA methylation, histone modifications, and other techniques based on the procedure. Studies on epigenetics are presently using a variety of histone changes, such as ubiquitination, acetylation, citrullination, methylation, and phosphorylation. Through the projection period, research efforts aimed at elucidating the function of histone modifications in both cancer and non-oncology uses are anticipated to support sector development.

Technological Insights:

The industry is divided into NGS, PCR & qPCR, mass spectrometry, sonication, and other methods based on methodology. The greatest revenue produced by the NGS segment in the industry for the year 2021 has been attributed to an increase in demand for NGS platforms among research experts seeking to acquire clinically insightful and exhaustive datasets. Additionally, due to their capacity to quickly sequence epigenomes, NGS solutions are getting popularity in mutational and epigenetic study activities. The industry for PCR and qPCR is anticipated to expand quickly and have the greatest CAGR during the forecast time. 

Application Insights:

The sector is expanding due to the growing incidence of cancer around the world and the rise in cancer-related fatalities. Non-oncology is anticipated to expand more quickly over the forecasted time. The strict R&D initiatives undertaken by private organizations and the biopharmaceutical sectors to find the epigenetic markers linked to these illnesses are responsible for the segment's growth. 

Recent Development:

  • In February 2021, Twist Bioscience Corporation revealed the Twist NGS Methylation Detection System, which aims to identify methylated zones within genetic material.
  • In February 2022, patients will start receiving OPDIVO and YERVOY as part of the Zenith Epigenetics Ltd. trial for solid tumor cancer, which is sponsored by the National Cancer Institute (NCI).
  • In February 2022, Element Biosciences, Inc. declared a collaboration with Dovetail Genomics.
  • In December 2020, Exact Sciences, a genetic testing company in the US, will buy Base Genomics for $140 million.

Major Key Players:

  • Bio-Rad
  • Illumina
  • Thermo Fisher
  • Active Motif
  • Diagenode
  • Agilent
  • Merck Millipore
  • Abcam
  • New England Biolabs
  • PerkinElmer
  • Zymo Research

Market Segmentation:

By Product

  • Kits
  • Reagents
  • Enzymes
  • Instruments and Consumables
  • Bioinformatic Tools

By Technology

  • DNA Methylation
  • Histone Modification
  • Other Technologies

By Application

  • Oncology
    • Solid Tumors
    • Liquid Tumors
  • Non - oncology
    • Metabolic Diseases
    • Developmental Biology
    • Immunology
    • Cardiovascular Diseases
    • Other

By End-User

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations 

Buy this Research Report@ https://www.precedenceresearch.com/checkout/2633

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333